Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice
- Authors
- Park, S.-S.[Park, S.-S.]; Eom, H.-S.[Eom, H.-S.]; Kim, J.S.[Kim, J.S.]; Koh, Y.[Koh, Y.]; Choi, C.W.[Choi, C.W.]; Lee, J.-J.[Lee, J.-J.]; Kim, K.[Kim, K.]; Suh, C.[Suh, C.]; Lee, J.H.[Lee, J.H.]; Min, C.-K.[Min, C.-K.]; Korean Multiple Myeloma Working Party[Korean Multiple Myeloma Working Party]
- Issue Date
- Jan-2019
- Publisher
- Oxford University Press
- Keywords
- CD38; Daratumumab; relapsed; refractory; multiple myeloma
- Citation
- Japanese journal of clinical oncology, v.49, no.1, pp.92 - 95
- Journal Title
- Japanese journal of clinical oncology
- Volume
- 49
- Number
- 1
- Start Page
- 92
- End Page
- 95
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/15960
- DOI
- 10.1093/jjco/hyy177
- ISSN
- 0368-2811
- Abstract
- Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3%. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2.7 months with 28.9% (95% CI, 9.0-52.8) of 6-month progression-free survival. All infusion-related reactions, including ≥Grade 3 back pain (6.3%) and dyspnea (6.3%), were manageable. The most common hematologic and non-hematological adverse events were anemia (62.5%) and upper respiratory infection (43.8%). ≥Grade 3 bacterial infectious adverse events were identified, including upper and lower respiratory infection (12.5% and 18.8%) and death following sepsis (6.3%). We observed acceptable outcomes of daratumumab monotherapy on relapsed or refractory multiple myeloma patients including even a few subjects with high comorbidity, despite relatively frequent infectious adverse events.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/15960)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.